Showing 6031-6040 of 21466 results for "".
- Not Just a Headache: Migraine Across Women’s Lifespan at WHAV 2025https://reachmd.com/news/not-just-a-headache-migraine-across-womens-lifespan-at-whav-2025/2483469/New York, NY — At the 2025 Women’s Health Annual Visit (WHAV), neurologists Dr. Jelena Pavlović (Albert Einstein College of Medicine) and Dr. Amaal Starling (Mayo Clinic) delivered a comprehensive session on migraine, highlighting its disproportionate impact on women, the influen
- Unlocking Asthma Remission: The Role of FeNO in Small Airwayshttps://reachmd.com/news/unlocking-asthma-remission-the-role-of-feno-in-small-airways/2483442/The clinical importance of small airways in asthma management is becoming ever clear, as reflected in contemporary guideline summaries, with new insights revealing their role in achieving remission-like control in selected patients. Innovative biomarkers such as Fractional Exhaled Nitric Ox
- Evaluating COVID Vaccine Safety for Pregnant Women and Children: Latest Findingshttps://reachmd.com/news/evaluating-covid-vaccine-safety-for-pregnant-women-and-children-latest-findings/2483454/Vaccination efforts in pregnancy and pediatric populations are underpinned by robust studies, supporting safety while addressing lingering concerns. Surveillance and education remain key components in increasing vaccine uptake among hesitant groups. Recent studies af
- Harnessing Exercise: A New Frontier in Reducing Drug Cravingshttps://reachmd.com/news/harnessing-exercise-a-new-frontier-in-reducing-drug-cravings/2483435/Amid rising pressures from substance use disorders, clinicians are increasingly considering exercise interventions not merely as an adjunct to treatment but as a component of comprehensive care. Emerging evidence from small trials and observational studies suggests that
- FDA Approves Topical Ruxolitinib for AD in Children Aged 2 and Uphttps://reachmd.com/news/fda-approves-topical-ruxolitinib-for-ad-in-children-aged-2-and-up/2483445/The US Food and Drug Administration (FDA) has approved ruxolitinib cream 1.5% (Opzelura) for the short-term and non-continuous chronic treatment of mild-to-moderate atopic dermatitis (AD) in non-immunocompromised children ages 2 and older whose disease is inadequate
- Sciton Launches Multi-Wavelength Resurfacing Laser Platformhttps://reachmd.com/news/sciton-launches-multi-wavelength-resurfacing-laser-platform/2483427/Sciton, Inc. has introduced HALO® TRIBRID™, a laser platform that integrates 3 wavelengths—2940 nm, 1927 nm, and 1470 nm—into a single resurfacing device. The system combines the company’s previously distinct technologies (HALO®, MOXI™, and Erbium Resurfacing) into one handpiece, allowing provide
- Redefining Neurosurgery: The Role of Robotics and Machine Learninghttps://reachmd.com/news/redefining-neurosurgery-the-role-of-robotics-and-machine-learning/2483399/Neurosurgery is at a pivotal juncture, where cutting-edge technological advances are forging paths to unprecedented levels of precision and improved patient outcomes. In this landscape, the integration of robotics and machine learning (ML) is more than just innovation—it’s a revolut
- Assessing the Value: Tirzepatide vs. Semaglutide in Obesity and Osteoarthritishttps://reachmd.com/news/assessing-the-value-tirzepatide-vs-semaglutide-in-obesity-and-osteoarthritis/2483409/The ongoing challenge in managing obesity and osteoarthritis lies in balancing clinical effectiveness with economic viability. Incretin-based therapies, including semaglutide and the dual GIP/GLP-1 agonist tirzepatide, are emerging at the forefront of this therapeutic crossroad.
- Harnessing NGAL for Early Detection and Management of Kidney Diseasehttps://reachmd.com/news/harnessing-ngal-for-early-detection-and-management-of-kidney-disease/2483401/Early detection of kidney disease remains a critical challenge, with traditional markers often providing insight only after significant damage has occurred. Enter NGAL—an early kidney injury biomarker showing promise for faster detection, though performance and adoption vary by clinical set
- Revolutionizing Dermatology: Emerging Therapies in Atopic Dermatitis and Psoriasishttps://reachmd.com/news/revolutionizing-dermatology-emerging-therapies-in-atopic-dermatitis-and-psoriasis/2483408/The ever-evolving landscape of dermatologic therapy presents both challenges and innovations, reshaping patient care with promising advancements particularly in the realm of atopic dermatitis and psoriasis. The biologic mechanisms that drive inflammation in atopic dermatitis also hig